EPAS1 and neoplasm: Given that HIF-2α is associated with worse tumor outcomes in some models [62,76,83,96,97] and have better outcomes in others [9,59,71,94,95,101], future work should first focus on the therapeutic consequences of HIF-2α inhibitors and stabilizers in pre-clinical and translational models to best understand how targeting HIF-2α may lead to clinical benefit.